BNTX Jun 2024 80.000 put
| Previous Close | 0.0700 |
| Open | 0.1000 |
| Bid | 0.0500 |
| Ask | 0.1500 |
| Strike | 80.00 |
| Expire Date | 2024-06-21 |
| Day's Range | 0.1000 - 0.1000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1.07k |
GlobeNewswireBioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company’s diversified immuno-oncology pipeline at the American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, Illinois, from May 31 to June 4, 2024. Moreover, in support of the Company’s ongoing CAR-T cell and individualized mRNA programs, BioNTech will also present epidemiological and real-world data from two observational studi
- Thomson Reuters StreetEvents
Q1 2024 Autolus Therapeutics PLC Earnings Call
Q1 2024 Autolus Therapeutics PLC Earnings Call
- GlobeNewswire
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
MAINZ, Germany, May 17, 2024 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) held its Annual General Meeting (“AGM”) today, May 17, 2024. A total of 87.51 per cent of the share capital was represented at the virtual assembly. There were 14 items on the agenda of the AGM. All resolutions proposed on the agenda items put to the vote at today’s AGM were approved by a large majority of the shareholders. “The past few years marked a leap in competence for BioNTech,” said He
